To better understand the role of platelets in the response to checkpoint inhibitor therapy, we first assessed the presence of platelets in PD-L1 negative lung cancer tissues (lung and metastatic lymph node), obtained at biopsy pre-treatment, from patients who were treated with PD-L1 checkpoint blockade. Here, CD274 is linked to lung cancer.